Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors

Sezgin, Canfeza; Karabulut, Bülent; Uslu, Rüçhan; Şanlı, Ulus Ali; Yüzer, Yıldıray; Göker, Erdem

doi:10.1080/00365520510023819

Cited by 31 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Age and sex are baseline characteristics of patients. Performance status, which was reported to be a significant risk factor for survival in nonresectable pancreatic cancer (Ishii et al , 1996; Ueno et al , 2000; Sezgin et al , 2005), can be determined by physical examinations, and the remaining factors by computed tomography, which is routinely performed for patients with unresectable pancreatic cancer. In addition, no specific molecular markers (Liu et al , 2012; Lee et al , 2013) are required for this nomogram.…”

Section: Discussionmentioning

confidence: 99%

“…Several prognostic factors for survival of nonresectable pancreatic cancer have been reported (Ishii et al , 1996; Ueno et al , 2000; Sezgin et al , 2005; Nakai et al , 2008, 2011), but were evaluated separately in different cohorts. One of the strengths of a nomogram is the ability to integrate multiple prognostic factors into a single numerical estimate of survival in an individual patient and thus provide an individualised prediction of survival.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy

et al. 2014

View full text Add to dashboard Cite

Background:A nomogram is progressively being used as a useful predictive tool for cancer prognosis. A nomogram to predict survival in nonresectable pancreatic cancer treated with chemotherapy has not been reported.Methods:Using prospectively collected data on patients with nonresectable pancreatic cancer receiving gemcitabine-based chemotherapy at five Japanese hospitals, we derived a predictive nomogram and internally validated it using a concordance index and calibration plots.Results:In total, 531 patients were included between June 2001 and February 2013. The American Joint Committee on Cancer (AJCC) TNM stages were III and IV in 204 and 327 patients, respectively. The median survival time of the total cohort was 11.3 months. A nomogram was generated to predict survival probabilities at 6, 12, and 18 months and median survival time, based on the following six variables: age; sex; performance status; tumour size; regional lymph node metastasis; and distant metastasis. The concordance index of the present nomogram was higher than that of the AJCC TNM staging system at 12 months (0.686 vs 0.612). The calibration plots demonstrated good fitness of the nomogram for survival prediction.Conclusions:The present nomogram can provide valuable information for tailored decision-making early after the diagnosis of nonresectable pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In patients with unresectable pancreatic cancer treated with gemcitabine, median PFS was reported as approximately 3 months [17]. Therefore, 6 months of PFS is significantly longer.…”

Section: Methodsmentioning

confidence: 97%

ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration

et al. 2011

View full text Add to dashboard Cite

show abstract

“…However, tumor cells often acquire resistance during or after gemcitabine treatment (Bergman, Andries M. et al, 2002; Andersson et al, 2009; Sezgin et al, 2005). Gemcitabine is a polar deoxycytidine analogue.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles

Lansakara-P

Rodriguez

Cui

2012

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Gemcitabine hydrochloride (HCl) is approved for the treatment of a wide spectrum of solid tumors. However, the rapid development of resistance often makes gemcitabine less efficacious. In the present study, we synthesized several novel lipophilic monophosphorylated gemcitabine derivatives, incorporated them into solid lipid nanoparticles, and then evaluated their ability to overcome major known gemcitabine resistance mechanisms by evaluating their in vitro cytotoxicities in cancer cells that are deficient in deoxycytidine kinase (dCK), deficient in human equilibrative nucleoside transporter (hENT1), over-expressing ribonucleotide reductase M1 subunit (RRM1), or over-expressing RRM2. In dCK deficient cells, the monophosphorylated gemcitabine derivatives and their nanoparticles were up to 86-fold more cytotoxic than gemcitabine HCl. The majority of the gemcitabine derivatives and their nanoparticles were more cytotoxic than gemcitabine HCl in cells that over-expressing RRM1 or RRM2, and the gemcitabine derivatives in nanoparticles were also resistant to deamination by deoxycytidine deaminase. The gemcitabine derivatives (in nanoparticles) hold a great potential in overcoming gemcitabine resistance.

show abstract

Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors

Abstract: Low PS is a negative predictive factor for the survival of patients with advanced pancreatic carcinoma treated with gemcitabine.

Cited by 31 publications

References 21 publications

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy

ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration

Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles

Contact Info

Product

Resources

About